FI117555B - Tumöravstötande antigenprekursorer, tumöravstötande antigener och användning av dem - Google Patents
Tumöravstötande antigenprekursorer, tumöravstötande antigener och användning av dem Download PDFInfo
- Publication number
- FI117555B FI117555B FI935174A FI935174A FI117555B FI 117555 B FI117555 B FI 117555B FI 935174 A FI935174 A FI 935174A FI 935174 A FI935174 A FI 935174A FI 117555 B FI117555 B FI 117555B
- Authority
- FI
- Finland
- Prior art keywords
- gag
- nucleic acid
- antigen
- ctg
- cells
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 137
- 239000000427 antigen Substances 0.000 title claims abstract description 136
- 102000036639 antigens Human genes 0.000 title claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 121
- 239000002243 precursor Substances 0.000 title claims description 34
- 230000002940 repellent Effects 0.000 title 2
- 239000005871 repellent Substances 0.000 title 2
- 210000004027 cell Anatomy 0.000 claims abstract description 255
- 108020004414 DNA Proteins 0.000 claims abstract description 78
- 230000009089 cytolysis Effects 0.000 claims abstract description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 108
- 150000007523 nucleic acids Chemical class 0.000 claims description 73
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 36
- 239000002299 complementary DNA Substances 0.000 claims description 31
- 238000001890 transfection Methods 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 19
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000009396 hybridization Methods 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 108020004635 Complementary DNA Proteins 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 206010053567 Coagulopathies Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000035602 clotting Effects 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000001461 cytolytic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 231100000588 tumorigenic Toxicity 0.000 claims description 2
- 230000000381 tumorigenic effect Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000053602 DNA Human genes 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101800001386 Peptide II Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 19
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 description 48
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 29
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 27
- 201000001441 melanoma Diseases 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 19
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 16
- 238000012737 microarray-based gene expression Methods 0.000 description 16
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 101150013341 pla gene Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 8
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 8
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 8
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 201000006512 mast cell neoplasm Diseases 0.000 description 4
- 208000006971 mastocytoma Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 101150084750 1 gene Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102220519838 Putative neutrophil cytosol factor 1B_P91A_mutation Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101150013191 E gene Proteins 0.000 description 2
- 241001200922 Gagata Species 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 101001005716 Homo sapiens Melanoma-associated antigen 11 Proteins 0.000 description 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 2
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 239000013601 cosmid vector Substances 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 that is Proteins 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LJYDIYITSYDTAY-LSBAASHUSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 LJYDIYITSYDTAY-LSBAASHUSA-N 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- DWYROCSXOOMOEU-CIUDSAMLSA-N Ala-Met-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N DWYROCSXOOMOEU-CIUDSAMLSA-N 0.000 description 1
- DXTYEWAQOXYRHZ-KKXDTOCCSA-N Ala-Phe-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N DXTYEWAQOXYRHZ-KKXDTOCCSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- JCROZIFVIYMXHM-GUBZILKMSA-N Arg-Met-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N JCROZIFVIYMXHM-GUBZILKMSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 description 1
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 1
- VJGQRELPQWNURN-JYJNAYRXSA-N Leu-Tyr-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJGQRELPQWNURN-JYJNAYRXSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102100025083 Melanoma-associated antigen 11 Human genes 0.000 description 1
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 1
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 102100031703 N-terminal kinase-like protein Human genes 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101710198346 Snaclec 5 Proteins 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- XQYHLZNPOTXRMQ-KKUMJFAQSA-N Tyr-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XQYHLZNPOTXRMQ-KKUMJFAQSA-N 0.000 description 1
- JXGUUJMPCRXMSO-HJOGWXRNSA-N Tyr-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JXGUUJMPCRXMSO-HJOGWXRNSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- VJOWWOGRNXRQMF-UVBJJODRSA-N Val-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 VJOWWOGRNXRQMF-UVBJJODRSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- 210000005221 acidic domain Anatomy 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000004959 laryngeal benign neoplasm Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200004009 rs36096184 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (26)
1. Isolerad nukleinsyramolekyl, som kodar för en tumöravstötande antigenföregängare, Vars komplementära se- 5 kvens hybridiseras med sekvens nr 8 vid stränga förhällan-den, som definierats som tvätt vid 65 °C 0,2 x SSC, 0. 1 x SSC, följt av 0,1 x SSC, 0,1 % SDS.
2. Isolerad nukleinsyramolekyl enligt patentkrav 1, kännetecknad av att den kodar för en humantumör-10 avstötande antigenföregängare (TRAP) eller en tumöravstötande antigen (TRA).
3. Isolerad nukleinsyramolekyl enligt patentkrav 1, kännetecknad av att den kodar för en medlem av familjen MAGE.
4. Expressionsvektor, kännetecknad av att den innehäller en nukleinsyramolekyl enligt nägot av pa-tentkraven 1-3 funktionellt länkad tili en promoter.
5. Expressionsvektor enligt patentkrav 4, kännetecknad av att den innehäller en nukleinsyramolekyl, 20 som kodar för en peptid som deriverats frän MAGE-1 och är funktionellt länkad tili en promoter. .·. 6. Expressionsvektor enligt patentkrav 5, kän- i "" netecknad av att den innehäller ett bakteriellt eller • 1 • · · * . viralt genom eller en del av det. * 1 1 · ·
7. Vid transfektering av en cell användbart ex- * 1 · : pressionssystem, kännetecknat av att det innehäller • 1 1 : (i) en första vektor, som innehäller en nukleinsyramole- t· V · kyl, som kodar för en tumöravstötande antigenföregängare, och (ii) en andra vektor, som är (a) en vektor, som inne- : 30 häller en nukleinsyramolekyl, som kodar för en MHC- eller • · · HLA-molekyl, som uppvisar en tumöravstötande antigen som ♦ · · 1. deriverats frän den tumöravstötande antigenföregängaren, • · · **|#1 eller (b) en vektor, som innehäller en nukleinsyramolekyl, • · *···1 som kodar för interleukin. • · · /: 92 117555
8. Förfarande för bestämning av regression, progression eller utbrott av cancersjukdom, kännetecknat av att frän ett prov frän en patient som lider av en even-tuell cancersjukdom bestäms en cellinjes lys genom inver- 5 kan av för den tumöravstötande antigenen specifika cytoly-tiska T-celler eller den tumöravstötande antigenföregänga-ren eller den avstötande antigenen bestäms medelst immun-analys, DNS-hybridisering eller polymeraskedjereaktion.
9. Förfarande enligt patentkrav 8, känneteck-10 nat av att nämnda prov är en kroppsvätska.
10. Förfarande enligt patentkrav 8, kännetecknat av att cellinjens lys bestäms genom inverkan av för ; den tumöravstötande antigenen specifika cytolytiska T-celler. 15 11. Förfarande enligt patentkrav 10, känne tecknat av att den tumöravstötande antigenföregängaren eller den avstötande antigenen bestäms medelst immunana-lys, DNA-hybridisering eller polymeraskedjereaktion.
12. Förfarande för framställning av sädant biolo-20 giskt material som är användbart vid behandling av en patient som lider av en cancers jukdom, kännetecknat av att (i) en värdcell transfekteras med en nukleinsyra- • · · * . molekyl, som kodar för eller exprimerar en tumöravstötande * · 25 antigenföregangare, * 1 · : (ii) nämnda värdcell transfekteras med en nuklein- Il I * · · : .2 syramolekyl, som kodar för en human-leukocytantigen (HLA), * · ·.· · som uppvisar en tumöravstötande antigen, som deriverats frän nämnda tumöravstötande antigenföregangare, pä en cell- : 30 yta och · · ·3: (iii) nämnda värdceller behandlas vid förhällan- * 1 1 ' den, som befrämjar expression av nukleinsyramolekylerna * · · och erbjudande av den tumöravstötande antigenen medelst • · *"·’ human-leukocytantigenen. · 2 * 3 • · · · 1 93 1 1 7555
13. Förfarande enligt patentkrav 12, k anne-tecknat av att det dessutom innehäller transfekterande av nämnda värdcell med en nukleinsyrasekvens, som kodar · för cytokin.
14. Isolerad nukleinsyramolekyl, kännetecknad av att nämnda molekyl är: a) en DNA-molekyl, som omfattar en nukleotidsek-vens, som har valts frän sekvenserna nr 7, 8, 9, 11, 12, 13, 15, 16, 18, 19, komplementära sekvenser av samma längd 10 eller delar av dem; eller b) vid stränga förhällanden tili en sädan DNA-molekyl hybridiserande med en nukleotidsekvens som har valts frän sekvenserna nr 7, 8, 9, 11, 12, 13, 15, 16, 18 och 19 och komplementära sekvenser av samma längd; 15 och kodar för eller är ett komplement av samma längd av en nukleinsyramolekyl, som kodar för en polypep-tid eller ett protein, som förmär ästadkomma ett cytoly-tiskt svar frän human-T-lymfocyter, när det presenteras pä en cellyta, eller en föregängare för en sadan polypeptid . 20 eller ett sädant protein.
15. Isolerad nukleinsyramolekyl enligt patentkrav 14, kännetecknad av att nämnda molekyl är cDNA, ge- . ;·] nomt DNA eller en RNA-molekyl. • ·· | . 16. Isolerad nukleinsyramolekyl, kännetecknad • · . . 25 av att den omfattar en RNA-trans kr ipt av en DNA-molekyl • · · enligt patentkrav 15. • · * : ·* 17. Isolerad nukleinsyramolekyl, kännetecknad • * * * · * *.* * av att den omfattar en nukleinsyrasekvens, som kodar för en polypeptid eller ett protein, som förmär ästadkomma ett 30 cytolytiskt svar frän T-lymfocyter, när det presenteras pä :***: en cellyta, eller en föregängare tili en sädan polypeptid eller ett sädant protein, som en nukleinsyramolekyl enligt • « · nägot av patentkraven 14 - 16 kodar för, eller en komple- • » *“·* mentär nukleinsyramolekyl av samma längd. • * ····· • * 117555 94
18. Isolerad nukleinsyramolekyl enligt nagot av patentkraven 14-17, kännetecknad av att näranda po-lypeptid eller protein omfattar en aminosyrasekvens, som är i sekvens nr 26. 5 19, Isolerad nukleinsyramolekyl enligt nagot av patentkraven 14 - 17, kännetecknad av att den kan hybridiseras vid stränga förhällanden med en sadan nukleinsyramolekyl som har en nukleotidsekvens som visats i nä-gon av sekvenserna nr 7, 8, 9 och 11 eller med en komple-10 mentär nukleotidsekvens av lämplig längd.
20. Isolerad nukleinsyramolekyl enligt patentkrav 19, kännetecknad av att den har nukleotidsekvensen som visats i figur 9 eller nägon av sekvenserna nr 7, 8, 9 och 11 eller en komplementär nukleotidsekvens av samma 15 längd.
21. Expressionsvektor, kännetecknad av att den omfattar en nukleinsyramolekyl enligt nagot av patentkraven 14-20.
22. Expressionsvektor enligt patentkrav 21, kän- 20 netecknad av att nukleinsyramolekylen är funktionellt länkad till en promoter. .:. 23. Expressionsvektor enligt patentkrav 21 eller Φ · · · ;·. 22, kännetecknad av att den dessutom omfattar en * · · 1 ^ nukleinsyrasekvens, som kodar för en MHC- eller HLA-mole- • · . , 25 kyl, cytokin, bakteriellt eller viralt genom eller en del • · · ··· · därav. • * · • » · 117555 95
26. Förfarande för att producera en cytolytisk T-cellodling, som är reaktiv mot en individs autologa tumör-celler, kännetecknat av att frän individen tas ett lymfocytprov och därefter odlas lymfocytprovet med celler, 5 som transfekterats med en nukleinsyramolekyl enligt nägot av patentkraven 14 - 20 eller en expressionsvektor enligt nagot av patentkraven 22-24. ! -i φφφ φφφ· ·· ! • · • ·· φ ••••e····· · • · • · ♦ ♦ · ··· ··· · ·· ♦ • · * • · ·*..·' • · · • · · • · · • · · • · « • · · • · · • φ * · • φ# φφφ *#· ♦ ···-· • φφφ φ φ φ · φφφ φ φ .< φ φ φ φ φ φ φ φ φ φ φφ φ φ φ
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70570291A | 1991-05-23 | 1991-05-23 | |
US70570291 | 1991-05-23 | ||
US72883891A | 1991-07-09 | 1991-07-09 | |
US72883891 | 1991-07-09 | ||
US76436491 | 1991-09-23 | ||
US07/764,364 US5327252A (en) | 1990-09-21 | 1991-09-23 | Print evaluation apparatus |
US80704391 | 1991-12-12 | ||
US07/807,043 US5342774A (en) | 1991-05-23 | 1991-12-12 | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US9204354 | 1992-05-22 | ||
PCT/US1992/004354 WO1992020356A1 (en) | 1991-05-23 | 1992-05-22 | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
FI935174A FI935174A (fi) | 1993-11-22 |
FI935174A0 FI935174A0 (fi) | 1993-11-22 |
FI117555B true FI117555B (sv) | 2006-11-30 |
Family
ID=27505492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI935174A FI117555B (sv) | 1991-05-23 | 1993-11-22 | Tumöravstötande antigenprekursorer, tumöravstötande antigener och användning av dem |
Country Status (13)
Country | Link |
---|---|
US (1) | US5342774A (sv) |
EP (1) | EP0595838B1 (sv) |
JP (1) | JP3484459B2 (sv) |
AT (1) | ATE279514T1 (sv) |
CA (2) | CA2109727C (sv) |
DE (1) | DE69233435T2 (sv) |
DK (1) | DK0595838T3 (sv) |
ES (1) | ES2225818T3 (sv) |
FI (1) | FI117555B (sv) |
IL (1) | IL101963A (sv) |
NO (1) | NO315051B1 (sv) |
PT (1) | PT100515B (sv) |
WO (1) | WO1992020356A1 (sv) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541104A (en) * | 1991-05-23 | 1996-07-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 |
US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
WO1994005304A1 (en) * | 1992-08-31 | 1994-03-17 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
US5462871A (en) * | 1992-08-31 | 1995-10-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
US6222012B1 (en) | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
DE69331813T4 (de) | 1992-12-22 | 2003-07-10 | Ludwig Inst Cancer Res | Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen |
CA2154468A1 (en) * | 1993-01-22 | 1994-08-04 | Pierre Van Der Bruggen | Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1 |
US6328971B1 (en) * | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
US5558995A (en) * | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5877017A (en) * | 1993-06-17 | 1999-03-02 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5610013A (en) * | 1993-07-22 | 1997-03-11 | Ludwig Institute For Cancer Research | Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors |
AU702517B2 (en) * | 1993-08-06 | 1999-02-25 | Epimmune, Inc. | Cloning and characterization of the complete MAGE-1 gene |
US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
FR2710536B1 (fr) * | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
DE69533295T3 (de) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
DE69524264T2 (de) * | 1994-03-01 | 2002-07-18 | Ludwig Inst Cancer Res | Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage |
US5512437A (en) * | 1994-03-01 | 1996-04-30 | Ludwig Institute For Cancer Research | Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3 |
US5763165A (en) * | 1994-03-10 | 1998-06-09 | Ludwig Institute For Cancer Research | Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 |
US5512444A (en) * | 1994-03-01 | 1996-04-30 | Ludwig Institute For Cancer Research | Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4 |
US5585461A (en) * | 1994-03-24 | 1996-12-17 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
US5554506A (en) * | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5851523A (en) * | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
JPH10505481A (ja) | 1994-04-22 | 1998-06-02 | アメリカ合衆国 | メラノーマ抗原 |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US5589334A (en) * | 1994-06-03 | 1996-12-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof |
US5977300A (en) * | 1994-06-03 | 1999-11-02 | Ludwig Institute Of Cancer Research | Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof |
US6060257A (en) * | 1994-06-03 | 2000-05-09 | Ludwig Institute For Cancer Research | Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof |
US5997870A (en) | 1994-06-03 | 1999-12-07 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B44 Molecules |
US5834245A (en) * | 1994-07-29 | 1998-11-10 | Cancer Institute | PRLTS proteins and DNA's encoding the same |
CA2201327A1 (en) * | 1994-09-30 | 1996-04-11 | Ludwig Institute For Cancer Research | Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | Us Gov Nat Inst Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
US7635479B2 (en) * | 2000-03-29 | 2009-12-22 | The Trustees Of The University Of Pennsylvania | Composition and methods for enhancing immunogenecity of antigens |
US8114414B2 (en) * | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
US20070264279A1 (en) * | 1994-11-08 | 2007-11-15 | Claudia Gravekamp | Compositions and methods comprising a MAGE-b antigen |
US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US8956621B2 (en) | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
US7662396B2 (en) * | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US7820180B2 (en) * | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
US6017705A (en) * | 1995-03-14 | 2000-01-25 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof |
US5759783A (en) * | 1995-03-14 | 1998-06-02 | Ludwig Institute For Cancer Research | Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene |
US5939526A (en) * | 1995-03-21 | 1999-08-17 | Ludwig Institute For Cancer Research | Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof |
US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
US6140464A (en) * | 1995-06-07 | 2000-10-31 | Ludwig Institute For Cancer Research | Nonapeptides that bind a HLA-A2.1 molecule |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
JPH11508767A (ja) * | 1995-06-29 | 1999-08-03 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | マウス腫瘍拒絶抗原前駆体smage−3をコードする単離核酸分子 |
US7501501B2 (en) * | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
AU726623B2 (en) * | 1996-02-21 | 2000-11-16 | Julianna Lisziewicz | Methods and compositions for protective and therapeutic genetic immunization |
CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
FR2746110B1 (fr) * | 1996-03-14 | 1998-04-17 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
US7297331B2 (en) * | 1996-04-03 | 2007-11-20 | The Rogosin Institute | Beads containing restricted cancer cells producing material suppressing cancer cell proliferation |
WO1997049817A1 (en) * | 1996-06-25 | 1997-12-31 | The Ludwig Institute For Cancer Research | Brain glycogen phosphorylase cancer antigen |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
AU3889997A (en) | 1996-08-16 | 1998-03-06 | Johns Hopkins University School Of Medicine, The | Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same |
US5908778A (en) | 1996-10-03 | 1999-06-01 | Ludwig Institute For Cancer Research | Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof |
US6087174A (en) * | 1996-12-26 | 2000-07-11 | Johns Hopkins University, School Of Medicine | Growth medium for primary pancreatic tumor cell culture |
US5912143A (en) * | 1996-12-27 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a human mage protein homolog |
WO1998032855A1 (en) * | 1997-01-27 | 1998-07-30 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
US6794131B1 (en) * | 1998-01-27 | 2004-09-21 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
US6087441A (en) | 1997-02-05 | 2000-07-11 | Ludwig Institute For Cancer Research | Structurally modified peptides that are resistant to peptidase degradation |
US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
US5879892A (en) | 1997-04-25 | 1999-03-09 | Ludwig Institute For Cancer Research | Leukemia associated genes |
US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
JP2001516009A (ja) * | 1997-07-17 | 2001-09-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ガン関連核酸及びポリペプチド |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US5965535A (en) * | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
US6210886B1 (en) | 1998-02-04 | 2001-04-03 | Ludwig Institute For Cancer Research | Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors |
DK1659178T3 (da) | 1998-02-05 | 2010-07-12 | Glaxosmithkline Biolog Sa | Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein |
US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
US5905145A (en) * | 1998-03-06 | 1999-05-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof |
US7001999B1 (en) | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US6245525B1 (en) | 1998-07-27 | 2001-06-12 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US6140050A (en) * | 1998-06-26 | 2000-10-31 | Ludwig Institute For Cancer Research | Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith |
US6686147B1 (en) | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
US6710172B1 (en) * | 1998-10-02 | 2004-03-23 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
DE69937966D1 (de) * | 1998-11-12 | 2008-02-21 | Cytomatrix Llc | Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system |
GB9826143D0 (en) | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
AU3389500A (en) * | 1999-03-02 | 2000-09-21 | Ludwig Institute For Cancer Research | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
US20080318889A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20080318890A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) * | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
ES2296615T3 (es) | 1999-04-08 | 2008-05-01 | Antisoma Research Limited | Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina. |
US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US6897288B1 (en) | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
US6448073B1 (en) | 2000-01-28 | 2002-09-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
US9012141B2 (en) * | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
AU5810201A (en) * | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
US7700344B2 (en) * | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
EP1752160A3 (en) | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitope sequences |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US7393657B2 (en) | 2001-04-12 | 2008-07-01 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: I |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
CA2474497C (en) | 2002-01-30 | 2013-12-03 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US7311914B2 (en) * | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
EP1545610A4 (en) * | 2002-09-06 | 2006-11-08 | Mannkind Corp | EPITOPE SEQUENCES |
AU2003283963A1 (en) | 2002-09-27 | 2004-04-19 | Ludwig Institute For Cancer Research | Mage-c2 antigenic peptides and uses thereof |
WO2004037284A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
CN103288920B (zh) | 2003-01-30 | 2015-08-12 | 苏瓦克有限公司 | 存活蛋白衍生肽及其用途 |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
EP1691824B1 (en) | 2003-11-19 | 2009-03-11 | Survac ApS | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
EP1743025A4 (en) * | 2004-03-29 | 2007-12-05 | Cytomatrix Llc | METHOD OF MANUFACTURING REGULATOR T CELLS AND THEIR USE |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
JP5118964B2 (ja) | 2004-06-23 | 2013-01-16 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 2粒子複合体を用いた生物学的分子の検出のための方法及び組成物 |
EP1833506B1 (en) * | 2004-12-29 | 2015-08-26 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
CA2594224A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
JP5805358B2 (ja) * | 2005-02-02 | 2015-11-04 | ブルース・ミルネ・ホール | 特異抗原に活性化したcd4+、cd25+t細胞 |
AU2006209951B2 (en) | 2005-02-04 | 2011-04-14 | Survac Aps | Survivin peptide vaccine |
JP5170976B2 (ja) | 2006-04-11 | 2013-03-27 | 株式会社イミュノフロンティア | タンパク質複合体およびその製造方法 |
EP2052076A4 (en) | 2006-08-02 | 2010-07-14 | Newsouth Innovations Pty Ltd | METHOD FOR IDENTIFYING ANY ANTIGEN-ACTIVATED, CD8-EXPRESSING CD4 + CD25 + T-CELLS |
US20080241069A1 (en) * | 2006-08-04 | 2008-10-02 | Yvonne Paterson | Methods and compositions for treating IgE-mediated diseases |
WO2008079172A2 (en) * | 2006-08-15 | 2008-07-03 | The Trustees Of The University Of Pennsylvania | Compositions comprising hmw-maa and fragments thereof, and methods of use thereof |
US8268326B2 (en) * | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
EP2853269B1 (en) | 2008-05-19 | 2019-05-01 | Advaxis, Inc. | Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein |
EP2328923B1 (en) | 2008-09-02 | 2016-01-13 | Cedars-Sinai Medical Center | Cd133 epitopes |
JP5539411B2 (ja) | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
KR20120002534A (ko) | 2009-03-17 | 2012-01-05 | 엠디엑스헬스 에스에이 | 유전자 발현의 향상된 검출 |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
CN104411327A (zh) | 2012-03-12 | 2015-03-11 | 阿德瓦希斯公司 | 李斯特菌疫苗治疗以后的抑制细胞功能抑制 |
US10137182B2 (en) | 2013-02-14 | 2018-11-27 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
CA3047707A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-41bbl fusion protein and methods of use thereof |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
WO2019006003A1 (en) | 2017-06-27 | 2019-01-03 | The Trustees Of Princeton University | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
WO2019145509A1 (en) | 2018-01-26 | 2019-08-01 | Cambridge Enterprise Limited | Peptide exchange protein |
US20210214417A1 (en) | 2018-07-11 | 2021-07-15 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
US20210379109A1 (en) | 2018-08-24 | 2021-12-09 | The Trustees Of Princeton University | Immunotherapy with metabolic enzyme expression |
GB201820444D0 (en) | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
WO2021005599A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
GB201911954D0 (en) | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Lentiviral transduction methods |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141742A (en) * | 1986-02-07 | 1992-08-25 | Oncogen | Vaccines against melanoma |
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
US5188959A (en) * | 1989-09-28 | 1993-02-23 | Trustees Of Tufts College | Extracellular matrix protein adherent t cells |
-
1991
- 1991-12-12 US US07/807,043 patent/US5342774A/en not_active Ceased
-
1992
- 1992-05-22 CA CA002109727A patent/CA2109727C/en not_active Expired - Lifetime
- 1992-05-22 EP EP92913925A patent/EP0595838B1/en not_active Expired - Lifetime
- 1992-05-22 AT AT92913925T patent/ATE279514T1/de active
- 1992-05-22 PT PT100515A patent/PT100515B/pt not_active IP Right Cessation
- 1992-05-22 CA CA002307317A patent/CA2307317C/en not_active Expired - Lifetime
- 1992-05-22 JP JP50033093A patent/JP3484459B2/ja not_active Expired - Lifetime
- 1992-05-22 ES ES92913925T patent/ES2225818T3/es not_active Expired - Lifetime
- 1992-05-22 IL IL10196392A patent/IL101963A/en not_active IP Right Cessation
- 1992-05-22 DK DK92913925T patent/DK0595838T3/da active
- 1992-05-22 WO PCT/US1992/004354 patent/WO1992020356A1/en active IP Right Grant
- 1992-05-22 DE DE69233435T patent/DE69233435T2/de not_active Expired - Lifetime
-
1993
- 1993-11-16 NO NO19934130A patent/NO315051B1/no not_active IP Right Cessation
- 1993-11-22 FI FI935174A patent/FI117555B/sv not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69233435D1 (de) | 2004-11-18 |
CA2307317A1 (en) | 1992-11-26 |
CA2307317C (en) | 2006-07-18 |
IL101963A0 (en) | 1992-12-30 |
NO934130D0 (no) | 1993-11-16 |
IL101963A (en) | 2004-03-28 |
CA2109727C (en) | 2000-07-25 |
PT100515B (pt) | 1999-08-31 |
ATE279514T1 (de) | 2004-10-15 |
EP0595838B1 (en) | 2004-10-13 |
NO934130L (no) | 1993-11-23 |
JPH06511144A (ja) | 1994-12-15 |
ES2225818T3 (es) | 2005-03-16 |
NO315051B1 (no) | 2003-06-30 |
PT100515A (pt) | 1993-08-31 |
EP0595838A4 (en) | 1995-10-25 |
DE69233435T2 (de) | 2005-03-03 |
FI935174A (fi) | 1993-11-22 |
WO1992020356A1 (en) | 1992-11-26 |
FI935174A0 (fi) | 1993-11-22 |
JP3484459B2 (ja) | 2004-01-06 |
DK0595838T3 (da) | 2005-01-31 |
EP0595838A1 (en) | 1994-05-11 |
US5342774A (en) | 1994-08-30 |
CA2109727A1 (en) | 1992-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI117555B (sv) | Tumöravstötande antigenprekursorer, tumöravstötande antigener och användning av dem | |
US6599699B1 (en) | Methods for diagnosing a disorder by assaying for MAGE-3 | |
AU698310B2 (en) | Determination of cancerous conditions by mage gene expression | |
AU686314B2 (en) | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides | |
US5612201A (en) | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor | |
US5925729A (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
AU690371B2 (en) | Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor | |
US6498021B1 (en) | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-8 and uses thereof | |
US7495074B2 (en) | Isolated proteins MAGE-4 and MAGE-41 | |
AU664560B2 (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
IE84173B1 (en) | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof | |
USRE40089E1 (en) | Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor | |
WO2004022589A1 (fr) | Marqueur tumoral et ses applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 117555 Country of ref document: FI |
|
MA | Patent expired |